Switzerland (CH)

Inhibition of Hedgehog Acyltransferase Alleviates the Profibrotic Effects of Transforming Growth Factor beta in Systemic Sclerosis (2017) Liang R, Kagwiria R, Dees C, Zhang Y, Distler O, Schett G, Distler J Conference contribution "Multimorbidity" as the manifestation of network disturbances. From nosology to the Meikirch model (2017) Bircher J, Hahn EG Journal article STAT3 As an Important Integrator of Profibrotic Pathways in Systemic Sclerosis (2017) Sumova B, Mallano T, Chen CW, Distler A, Bergmann C, Distler O, Schett G, et al. Conference contribution TGF beta-Dependent Upregulation of XIAP Fosters Fibroblast Activation and Tissue Fibrosis By Promoting Canonical Wnt Signaling (2017) Bergmann C, Hallenberger L, Brandt A, Merlevede B, Dees C, Chen CW, Beyer C, et al. Conference contribution The Histone Demethylase Jumonji Domain-Containing Protein 3 (JMJD3) As Central Mediator of Fibroblast Activation (2017) Bergmann C, Brandt A, Dees C, Zhang Y, Chen CW, Mallano T, Wohlfahrt T, et al. Conference contribution TGF beta Promotes Fibrosis By MYST1-Dependent Epigenetic Regulation of Autophagy (2017) Zehender A, Lin NY, Stefanica A, Chen CW, Soare A, Wohlfahrt T, Rauber S, et al. Conference contribution TGF-beta-Induced Epigenetic Silencing of SOCS3 Facilitates STAT3 Signaling to Promote Fibroblast Activation and Tissue Fibrosis in Systemic Sclerosis (2017) Dees C, Zhang Y, Pötter S, Bergmann C, Distler O, Schett G, Distler J, Ramming A Conference contribution Secukinumab Treatment of moderate to severe Plaque Psoriasis in the clinical Routine Care: Baseline Data from the PROSPECT Study on Psoriasis Pre-treatment (2017) Von Kiedrowski R, Korber A, Kraehn-Senftleben G, Sticherling M, Lange L, Bachhuber T, Kasparek TR, et al. Conference contribution Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis without previous Systemic Therapy for Improvement of Skin Symptoms: PASI and IGA mod. 2011-Results of the PRIME Study (2017) Reich K, Mrowietz U, Augustin M, Thaci D, Kneidl J, Hentschke C, Simang M, et al. Conference contribution Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis without prior System Therapy with respect to the Improvement of quality of life: DLQI and SF-36 Results of the PRIME Study (2017) Augustin M, Thaci D, Reich K, Mrowietz U, Kneidl J, Hentschke C, Simang M, et al. Conference contribution